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Abstract: Intensive blood pressure (BP) lowering in patients with hypertension at increased risk of
cardiovascular disease has been associated with a lowered risk of incident atrial fibrillation (AF).
It is uncertain whether maintaining the optimal BP levels can prevent AF in the general elderly
population. We included 115,866 participants without AF in the Korea National Health Insurance
Service-Senior (≥60 years) cohort from 2002 to 2013. We compared the influence of BP on the
occurrence of new-onset AF between octogenarians (≥80 years) and non-octogenarians (<80 years)
subjects. With up to 6.7 ± 1.7 years of follow-up, 4393 incident AF cases occurred. After multivariable
adjustment for potentially confounding clinical covariates, the risk of AF in non-octogenarians was
significantly higher in subjects with BP levels of <120/<80 and ≥140/90 mm Hg, with hazard ratios
of 1.15 (95% confidence interval (CI), 1.03–1.28; p < 0.001) and 1.14 (95% CI, 1.04–1.26; p < 0.001),
compared to the optimal BP levels (120–129/<80 mm Hg). In octogenarians, the optimal BP range
was 130–139/80–89 mm Hg, higher than in non-octogenarians. A U-shaped relationship for the
development of incident AF was evident in non-octogenarians, and BP levels of 120–129/<80 mm Hg
were associated the lowest risk of incident AF. Compared to non-octogenarians, the lowest risk of AF
was associated with higher BP levels of 130–139/80–89 mm Hg amongst octogenarians.
Keywords: atrial fibrillation; hypertension; elderly; prevention
1. Introduction
Hypertension is the most common comorbidity in patients with atrial fibrillation (AF) and is
highly prevalent in patients with AF, especially those aged over 60 years [1]. Elevated blood pressure
(BP) is associated with a greater burden of AF [2] and every 20 mm Hg increase in systolic blood
pressure (SBP) has a 21% higher risk of AF [3]. The high incidence of hypertension with AF has
prompted the argument that AF is another sign of hypertensive target organ damage [4–6].
Several epidemiological studies have shown that the levels of SBP 130–139 mm Hg are also
associated with increased risk of AF, compared to normal SBP (<120 mm Hg) [7–10]. Several
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randomized controlled trials also showed the relationship between BP and risk of AF. In the Cardio-Sis
trial (Controllo della Pressione Arteriosa Sistolica trial), the risk of new-onset AF was reduced in the
tight control group (SBP < 130 mm Hg) compared to the usual control group (SBP < 140 mm Hg) in
patients with hypertension without diabetes [11]. Other report have shown that the intensive therapy
group (target SBP < 120 mm Hg) did not show statistical significance with respect to the incidence of
AF in patients with hypertension and diabetes [12]. A recent study, using data from Systolic Blood
Pressure Intervention Trial (SPRINT) found that intensive treatment with a target SBP of <120 mm
Hg in patients with hypertension at high risk of cardiovascular disease reduced the risk of AF [13].
However, the relationship of BP and incident AF has not been established in older subjects.
However, strict BP control can induce serious adverse events such as hypotension, syncope,
electrolyte imbalance, and acute kidney injury [14]. The Elderly population is more likely have
other risk factors and target organ damage that may be worsened by lowering BP than the younger
population [15]. Exacerbation of postural hypotension could be associated with injurious falls, and a
low BP targets could be related to an increased risk of reduced renal function amongst octogenarians
(age > 80 years) [16]. Of note, the 2018 European Society of Cardiology (ESC) and the European Society
of Hypertension (ESH) guidelines recommend less strict BP control for the elderly (age ≥ 65 years) and
close monitoring of adverse effects. Additionally, a previous study suggests that intensive BP control
had no more benefit than harm in patients with a 10 year-cardiovascular risk of <18.2% [17].
It remains uncertain whether intensive BP lowering to a target SBP of <120 mm Hg results in
further lowering of the risk of new-onset AF in octogenarians with hypertension. In this study using the
nationwide population-based National Health Insurance Service (NHIS)-senior cohort (NHIS-Senior),
we aimed to investigate the optimal BP levels for the prevention of incident AF, defining the ideal BP
threshold for the prevention of AF in the general elderly population. Second, we evaluated whether
these associations were observed in different age groups and were influenced by strict BP control.
2. Experimental Section
Data were collected from the NHIS-Senior, which included about 558,147 individuals,
accounting for approximately 10% of the total elderly population over 60 years old in South Korea
(approximately 5.1 million) in 2002 [18]. The NHIS-Senior database included the following parameters:
sociodemographic and socioeconomic information, insurance status, health checkup examinations, and
records of patients’ medical and dental history. These parameters have been stratified to cover 12 years
(2002–2013) and anonymized in the cohort study to protect the privacy of individuals. This study
was approved by the Institutional Review Board of Yonsei University Health System (4-2016-0179).
Informed consent was waived. The NHIS-Senior database used in this study (NHIS-2016-2-171) was
made by the NHIS of Korea. The authors declare no conflict of interest with the NHIS.
2.1. BP Measurement
BP measurements were obtained at local hospitals and clinics certified for medical health
examination centers by the Korean National Health Insurance Corporation. After the patient rested for
5 min in the sitting position, brachial BP was measured by qualified medical personnel at each health
examination center. A blood pressure (BP) measurement was repeated if the first measurement was
>120/80 mm Hg. Automatic oscillometric devices and mercury sphygmomanometers were used for BP
measurements, with the choice of device being at the discretion of individual examination centers.
The preferred recommendation stipulated the use of mercury sphygmomanometers until 2015, when
the sale of mercury sphygmomanometers was banned. The average of the BP measured at the first and
second medical examinations was used for analysis.
2.2. Study Population
From the Korean NHIS-Senior, a total of 312,736 patients who had a health checkup between
2005 and 2012 were enrolled, and follow-up data were reviewed until December 2013. The exclusion
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criteria were as follows: (i) patients who had AF before enrollment (n = 8873); (ii) those who had heart
failure (HF) before enrollment (n = 26,210); (iii) those who had ischemic stroke or transient ischemic
attack before enrollment (n = 32,344); (iv) those who had myocardial infarction (MI) before enrollment
(n = 3944); (v) those who had hemorrhagic stroke before enrollment (n = 1149); (vi) those who had
malignancy before enrollment (n = 25,436); (vii) those who had missing data (n = 120); and (viii) those
who check BP once (n = 98,794). Finally, we included 115,866 patients with repeated BP measurement
(Figure 1).
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considered to have comorbid condition when the condition was a discharge diagnosis or confirmed 
at least twice in an outpatient setting according to previous studies using the NHIS (Supplementary 
Materials Table S1) [19,20]. For the status of standard income, the total amount of national health 
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Figure 1. Flowchart of the study population enrollment and analyses. NHIS, National Health Insurance
Service; TIA, transient ischemic attack; MI, myocardial infarction; BP, blood pressure; AF, atrial
fibrillation. * Korean National Health Insurance Service (NHIS)-Senior cohort. † Complete checkup
includes smoking, physical activity, alcohol, BMI, Total cholesterol, blood pressure, fasting glucose.
2.3. Covariates
We obtained information on selected comorbidities in inpatient and outpatient hospital diagnoses.
Baseline comorbidities were defined using the medical claims and information about prescription
medication prior to the index date. To ensure the accuracy of diagnosis, the patients w re con idered
to hav comorbid condition when the cond tion was a discharge diagnosis or confirmed at least twice
in an outpatient setting acc rding to previous studi s using the NHIS (Supplem nt ry Materials
Tabl S1) [19,20]. For the status of standard income, he tot l mount of natio al health insurance
premiums paid by the insured in the year was evaluated in proportio to personal incom .
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2.4. Hypertension and Atrial Fibrillation
Hypertension was defined as the combination of previous hypertension diagnosis (International
Classification of Disease-10th Revision (ICD-10) codes) and use of one or more antihypertensive drugs.
The hypertension onset date for duration calculations was determined using information on the first
date of hypertension diagnosis. The BP status was divided into four groups: (i) SBP of <120 mm Hg
and diastolic blood pressure (DBP) of <80 mm Hg; (ii) SBP of 120–129 mm Hg and DBP of <80 mm Hg;
(iii) SBP of 130–139 mm Hg or DBP of 80–90 mm Hg; and (iv) SBP of ≥140 mm Hg or DBP of ≥90 mm
Hg. The study also compared the SBP status and incidence of AF. Furthermore, the relationship
between the DBP status and incidence of AF was analyzed.
AF was diagnosed using the ICD-10, code I48. To ensure diagnostic accuracy, the patients were
defined as having AF only when it was a discharge diagnosis or had been confirmed at least twice in
the outpatient department. This AF diagnosis definition has been previously validated in the NHIS
database with a positive predictive value of 94.1% [19,21].
2.5. Statistical Analysis
The baseline characteristics of participants with age over and under 80 years were compared using
Student’s t-test and Pearson’s chi-square test. The incidence rates of events were calculated by dividing
the number of events by person-times at risk, with the 95% confidence intervals (CI) estimated by exact
Poisson distributions. Cox proportional hazards regressions were used to compare the incidence of AF
with BP status. Two-sided p-values <0.05 were considered statistically significant. Statistical analyses
were conducted using Statistical Package for Social Sciences (SPSS) version 23.0 (Chicago, IL, USA)
and R version 3.3.2 (The R Foundation, www.R-project.org).
3. Results
3.1. Baseline Characteristics
Compared with non-octogenarians, the octogenarians were predominantly female and had more
comorbidities, including hypertension, chronic kidney disease (CKD), anemia, chronic obstructive
pulmonary disease, and osteoporosis (Table 1). The low rates of CKD and diabetes for ages in this
study might be related with the rigid exclusion criteria of this study. The comparisons of baseline
characteristics among patients with different BP levels in non-octogenarians and octogenarians are
presented in Supplementary Materials Table S2.








(n = 7831) p-Value
Age, years 71.7 (69.5–74.6) 71.2 (69.3–74.0) 82.2 (81.0–84.5) <0.001
Male 53,609 (46.3) 50,391 (46.6) 3218 (41.1) <0.001
Systolic BP 130.5 (122.5–140.0) 130.0 (122.5–140.0) 132.5 (124.5–142.5) <0.001
Diastolic BP * 79.5 (74.0–85.0) 79.5 (74.0–85.0) 79.5 (73.5–85.0) 0.017
Economic state * 7.0 (4.0–9.0) 7.0 (4.0–9.0) 7.0 (3.0–9.0) 0.001
Alcohol <0.001
No drinking 64,681 (80.9) 60,075 (80.6) 4606 (85.8)
Moderate drinking 5982 (7.5) 5673 (7.6) 309 (5.8)
Heavy drinking † 9243 (11.6) 8789 (11.8) 454 (8.5)








(n = 7831) p-Value
Smoking <0.001
Non-smoker
or quit ≥12 months 63,389 (79.3) 58,993 (79.1) 4396 (81.9)
Quit <12 months 5732 (7.2) 5351 (7.2) 381 (7.1)
Current smoker 10,785 (13.5) 10,193 (13.7) 592 (11.0)
Comorbidities
Hypertension 46,519 (40.1) 42,883 (39.7) 3636 (46.4) <0.001
Diabetes 14,767 (12.7) 13,881 (12.8) 886 (11.3) <0.001
Dyslipidemia 34,200 (29.5) 32,369 (30.0) 1831 (23.4) <0.001
Chronic kidney disease 997 (0.9) 913 (0.8) 84 (1.1) 0.041
Anemia 17,715 (15.3) 15,715 (14.6) 2000 (25.6) <0.001
Hyperthyroidism 2462 (2.1) 2341 (2.2) 121 (1.5) <0.001
Hypothyroidism 2725 (2.4) 2583 (2.4) 142 (1.8) 0.001
COPD 6960 (6.0) 6262 (5.8) 698 (8.9) <0.001
Liver disease 23,559 (20.3) 22,335 (20.7) 1224 (15.6) <0.001
HCMP 156 (0.1) 149 (0.1) 7 (0.1) 0.331
Osteoporosis 33,139 (28.6) 30,569 (28.3) 2570 (32.8) <0.001
Medications
Aspirin 19,315 (16.7) 17,957 (16.6) 1358 (17.3) 0.102
P2Y12 inhibitor 872 (0.8) 816 (0.8) 56 (0.7) 0.742
ACE-inhibitor/ARB 18,425 (15.9) 17,110 (15.8) 1315 (16.8) 0.027
Beta blocker 18,115 (15.6) 16,815 (15.6) 1300 (16.6) 0.015
Calcium channel blocker 30,370 (26.2) 27,945 (25.9) 2425 (31.0) <0.001
Statin 11,918 (10.3) 11,333 (10.5) 585 (7.5) <0.001
Diuretics 23,665 (20.4) 21,728 (20.1) 1937 (24.7) <0.001
MRA 1677 (1.4) 1533 (1.4) 144 (1.8) 0.003
BP, blood pressure; COPD, chronic obstructive pulmonary disease; HCMP, hypertrophic cardiomyopathy; ACE,
angiotensin converting enzyme; ARB, angiotensin II receptor blocker; MRA, mineralocorticoid receptor antagonist.
* Several parameters including diastolic BP, economic state showed exactly the same median values. However,
still significant (admittedly p < 0.05) statistical differences because significantly different quartile values. †Male:
>112 g/week or >42 g/day, Female: >56 g/week or >28 g/day. (14g per a glass). Values are presented as median
(Q1-Q3 quartiles (25th and 75th percentiles)) or %.
3.2. BP and Incident AF in Different Age Groups
During 6.4 ± 2.1 years of follow-up and a total of 768,314 person-years, 4393, 3946, and 447
incident AF cases occurred in the overall, non-octogenarian, and octogenarian populations, respectively.
The spline curves of the SBP and DBP and risk of AF in different age groups are presented in Figure 2.
A U-shaped relationship between SBP or DBP and risk of AF was evident; however, the U-shaped
relationship for SBP was not observed in the octogenarian population. There is the larger uncertainty
in the older group because it is numerically small. The optimal SBP level associated with the lowest
the risks of AF was 120–129 mm Hg in the overall population and the non-octogenarian population.
The optimal DBP level with the lowest risk of AF was 70–79 mm Hg.
After multivariable adjustment for potentially confounding clinical covariates, in non-
octogenarians, the risk of AF was higher in patients with BP levels of <120/<80 and ≥140/90 mm Hg
with adjusted hazard ratios (HR) of 1.15 (95% CI, 1.03–1.28, p < 0.001) and 1.14 (95% CI, 1.04–1.26,
p < 0.001), respectively, compared to BP levels of 120–129/<80 mm Hg. Amongst octogenarians, the risk
of AF was significantly higher in patients with BP levels of ≥140/90 mm Hg with an HR of 1.26 (95%
CI, 1.01–1.58, p < 0.001) compared with the optimal BP level (130–139/80–90 mm Hg; Table 2, Figure 3).
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Table 2. Incidence Rate of Atrial Fibrillation According to Blood Pressure.
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3.3. BP and Incident AF in Patients with Treated Hypertension
With a total of 298,087 person-years follow-up of patients with treated hypertension, there were
2069, 1846, and 3636 incident AF cases occurring in the overall, non-octogenarian, and octogenarian
populations, respectively. The spline curves of the SBP and DBP and risk of AF in different age groups
are presented in Figure 4 and had a similar pattern as the spline curve for the general populations
(Figure 2).
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Figure 4. Systolic and diastolic blood pressure status of repeated measurement and risk of atrial
fibrillation among elderly populations with antihypertensive medications: (a) systolic blood pressure
and (b) diastolic blood pressure. SBP, systolic blood pressure; DBP, diastolic blood pressure. The blue
line shows relationship between hazard ratio of new-onset AF and blood pressure, and the gray area
indicates the degree of confidence.
After multivariable adjustment for potentially confounding clinical covariates in the
non-octogenarian population, the risk of AF was higher in patients with intensive BP control
(<120/<80 mm Hg) and poor (≥140/90 mm Hg) BP control with adjusted HRs of 1.37 (95% CI,
1.13–1.65, p < 0.001) and 1.16 (95% CI, 1.0–1.33, p < 0.001), respectively, compared to those with optimal
BP control (120–129/<80 mm Hg). In octogenarians, the risk of AF was significantly higher in patients
with a BP levels of ≥140/90 mm Hg with an HR of 1.42 (95% CI, 1.04–1.93, p <0.001) compared to those
with optimal BP level (130–139/80–90 mm Hg; Table 3, Figure 5).
J. Clin. Med. 2020, 9, 2988 9 of 16
Table 3. Incidence Rate of Atrial Fibrillation According to Blood Pressure in Patients with Treated Hypertension.
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Figure 5. Blood pressure status of repeated measurement and risk of atrial fibrillation among
elderly populations with antihypertensive medications: (a) overall population, (b) age < 80 years,
and (c) age ≥ 80 years.
3.4. Serious Adverse Events according to BP Status in Different Age Groups
The incidence rate and HR of serious adverse events according to BP status in patients with
hypertension treatment are presented in Table 4. In octogenarians, patients with intensive BP control
(<120/<80 mm Hg) showed more hypotension requiring hospitalization than those with a BP levels of
130–139/80–90 mm Hg with an adjusted HR of 2.06 (95% CI, 1.12–3.81, p < 0.001). The composite adverse
events (including hypotension requiring hospitalization, syncope, bradycardia, electrolyte abnormality,
injurious falls, and acute kidney injury) were numerically more frequent but non-statistically
significant in patients with intensive and optimal BP control compared to those with a BP level
of 130–139/80–89 mm Hg.
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Table 4. Incidence Rate and Hazard Ratio of Serious Adverse Events According to Blood Pressure Status in Patients with Hypertension Treatment.
Blood Pressure Status
<120/80 mmHg 120–129/<80 mmHg 130–139/80–89 mmHg ≥140/90 mmHg
Overall No. of total 4159 7466 17,268 17,626
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Table 4. Cont.
Blood Pressure Status
<120/80 mmHg 120–129/<80 mmHg 130–139/80–89 mmHg ≥140/90 mmHg
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4. Discussion
In this large nationwide study on the impact of hypertension on incident AF, our principal
findings are that BP levels of 120–129/<80 mm Hg were associated with a lower risk of incident AF in
non-octogenarians. Amongst octogenarians, an average 10 mm Hg higher BP level of 130–139/80–89 mm
Hg was more optimal to prevent AF. Second, octogenarians with intensive BP control (<120/<80 mm
Hg) showed more hypotension requiring hospitalization compared with BP level of 130–139/80–90 mm
Hg. Hence, a less strict BP level may be better to prevent AF and adverse effects amongst octogenarians.
The relationship between high BP and high incidence of AF supports the importance of BP control to
prevent AF in patients with hypertension. Hypertension is the most common and important modifiable
AF risk factor [2,3,22,23]. In a SPRINT sub-analysis, intensive BP control targeting SBP < 120 mm Hg
was related with a lower risk of new-onset AF [13]. In contrast, the present study found a U-shaped
relationship was observed between BP and incident AF in both non-octogenarians and octogenarians.
This U-shaped relationship could be related to several unique aspects of our study cohort.
The present study recruited participants aged over 60 years, with the median age of our population
being 71.7 years, much older than previous studies [11–13], and 6.8% of overall population were
individuals of age over 80 years. The elderly population had more comorbidities, and these factors
may influence the U-shaped relationship. Since the incidence of AF increases with age, we evaluated
the relationship between the optimal BP and AF risk for BP management in older individuals. When
comparing the relationship between AF and DBP, a U-shaped pattern was also observed in the overall
population and patients with hypertension.
4.1. Optimal BP Levels and Incident AF in Octogenarians
Amongst octogenarians, an average 10 mm Hg higher BP level of 130–139/80–89 mm Hg was
more optimal to prevent AF; this compares to non-octogenarians where the optimal BP level was
120–129/<80 mm Hg. However, the management of hypertension in octogenarians offers more
challenges than in non-octogenarians. Elderly patients (age > 80 years) have more comorbidities
and higher risks other organ damage than patients aged under 80 years. In old patients, physicians
should consider the risks and benefits when controlling BP due to aggravation of postural hypotension
and reduction of renal function [16]. Also, intensive BP control has been related to increased serious
adverse events such as hypotension, syncope, electrolyte abnormalities, and acute kidney injury [14].
Our results show an increased risk of hypotension requiring hospitalization in the intensive BP control
group (BP < 120/80 mm Hg) compared with BPs 130–139/80–89 mm Hg. Even though other adverse
events did not show significant differences, the composite outcome of adverse events showed a trend
towards an increased risk in patients with intensive control (BP < 120/80 mm Hg) and optimal BP
control (120–129/<80 mm Hg) compared to patients with BP levels of 130–139/80–89 mm Hg.
4.2. Limitations
The study has several limitations. First, in such studies using administrative databases, coding
inaccuracies can lead to errors. Hence, we applied the definition that we had already validated
in previous studies to minimize the problem [21,24–28]. Second, since the health examination of
individuals was conducted in different hospitals and clinics, a uniformity of BP measurement could not
be achieved. Third, the arbitrary cut-offs across continuous distributions (e.g., age, BP) were used to
compare groups using simple binary statistical tests in this study. While the simplification can illustrate
possible trends, it does automatically lead to a loss of detail in data analysis. Fourth, those who survive
into their ninth decade are already a positively selected group and presumably with useful healthy
characteristics. Fifth, since data about the types of AF and differential diagnosis between AF and
atrial flutter (AFL) were not available, we could not investigate about the difference of optimal BP
level according to the types of AF or AFL. Finally, hypertension and AF are associated with renal
dysfunction. In our study, CKD was defined using the medical record with ICD-10 codes. There was
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no data on proteinuria. The lack of data on proteinuria, which is one of the criteria for CKD, may lead
to low accuracy in defining CKD. This is one of the limitations of the study. Despite these limitations,
the study is the first assessment to investigate the association between BP levels and incidental AF in a
nationwide elderly population.
5. Conclusions
A U-shaped relationship for the development of incident AF was evident in non-octogenarians,
and BP levels of 120–130/<80 mm Hg were associated the lowest risk of incident AF. Compared to
non-octogenarians, the lowest risk of AF was associated with higher BP levels of 130–139/80–89 mm
Hg amongst octogenarians.
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